These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 34823756)

  • 1. Messenger RNA vaccines and neutralizing anti-severe acute respiratory syndrome coronavirus 2 antibodies in patients with immunodeficiency.
    Mungmunpuntipantip R; Wiwanitkit V
    Ann Allergy Asthma Immunol; 2021 Dec; 127(6):703. PubMed ID: 34823756
    [No Abstract]   [Full Text] [Related]  

  • 2. Strong Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody Response of Previously Infected Healthcare Workers Given 1 Dose of mRNA Vaccine.
    Dimeglio C; Herin F; Da-Silva I; Porcheron M; Martin-Blondel G; Miedougé M; Izopet J
    Clin Infect Dis; 2022 Mar; 74(4):746. PubMed ID: 34157078
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
    Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immediate Reactions After the First Dose of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Messenger RNA Vaccines Do Not Preclude Second-Dose Administration.
    Vanijcharoenkarn K; Lee FE; Martin L; Shih J; Sexton ME; Kuruvilla ME
    Clin Infect Dis; 2021 Dec; 73(11):2108-2111. PubMed ID: 33989390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
    Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
    J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [SARS-CoV-2 vaccines].
    Benfield TL; Helweg-Larsen J
    Ugeskr Laeger; 2021 Mar; 183(10):. PubMed ID: 33734065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mRNA vaccine effectiveness against asymptomatic severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection over seven months.
    Tande AJ; Pollock BD; Shah ND; Binnicker M; Berbari EF
    Infect Control Hosp Epidemiol; 2022 Mar; 43(3):393-395. PubMed ID: 34486511
    [No Abstract]   [Full Text] [Related]  

  • 10. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in mRNA vaccines for viral diseases.
    Huang Y; Zhu X; Guo X; Zhou Y; Liu D; Mao J; Xiong Y; Deng Y; Gao X
    J Med Virol; 2023 Jul; 95(7):e28924. PubMed ID: 37417396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing antibodies mediate virus-immune pathology of COVID-19.
    Jacobs JJL
    Med Hypotheses; 2020 Oct; 143():109884. PubMed ID: 32512289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic Messenger RNA-Based Vaccines: from Scorn to Hype.
    Pascolo S
    Viruses; 2021 Feb; 13(2):. PubMed ID: 33572452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRNA Vaccines Are Effective at Preventing COVID-19 in U.S. Health Care Personnel.
    Am J Nurs; 2022 Mar; 122(3):13. PubMed ID: 35200173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19: Significance of antibodies.
    Assadiasl S; Fatahi Y; Zavvar M; Nicknam MH
    Hum Antibodies; 2020; 28(4):287-297. PubMed ID: 32986664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.
    Jiang S; Hillyer C; Du L
    Trends Immunol; 2020 May; 41(5):355-359. PubMed ID: 32249063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants.
    Pishesha N; Harmand TJ; Rothlauf PW; Praest P; Alexander RK; van den Doel R; Liebeskind MJ; Vakaki MA; McCaul N; Wijne C; Verhaar E; Pinney W; Heston H; Bloyet LM; Pontelli MC; Ilagan MXG; Jan Lebbink R; Buchser WJ; Wiertz EJHJ; Whelan SPJ; Ploegh HL
    Proc Natl Acad Sci U S A; 2021 Nov; 118(44):. PubMed ID: 34654739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study.
    Li J; Hui A; Zhang X; Yang Y; Tang R; Ye H; Ji R; Lin M; Zhu Z; Türeci Ö; Lagkadinou E; Jia S; Pan H; Peng F; Ma Z; Wu Z; Guo X; Shi Y; Muik A; Şahin U; Zhu L; Zhu F
    Nat Med; 2021 Jun; 27(6):1062-1070. PubMed ID: 33888900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing SARS-CoV-2.
    Poeschla E
    Elife; 2020 Dec; 9():. PubMed ID: 33320086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The kinetics of viral load and antibodies to SARS-CoV-2.
    Sun J; Tang X; Bai R; Liang C; Zeng L; Lin H; Yuan R; Zhou P; Huang X; Xiong Q; Peng J; Cui F; Ke B; Su J; Liu Z; Lu J; Tian J; Sun R; Ke C
    Clin Microbiol Infect; 2020 Dec; 26(12):1690.e1-1690.e4. PubMed ID: 32898715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.